COSMIN systematic review and meta-analysis of the measurement properties of the PANSS-6

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology Pub Date : 2025-03-09 DOI:10.1016/j.euroneuro.2025.02.008

Simon Geck , Maximilian Roithmeier , Markus Bühner , Sophia Wehr , Lucia Weigel , Josef Priller , John M. Davis , Stefan Leucht

{"title":"COSMIN systematic review and meta-analysis of the measurement properties of the PANSS-6","authors":"Simon Geck , Maximilian Roithmeier , Markus Bühner , Sophia Wehr , Lucia Weigel , Josef Priller , John M. Davis , Stefan Leucht","doi":"10.1016/j.euroneuro.2025.02.008","DOIUrl":null,"url":null,"abstract":"<div><div>The Positive and Negative Syndrome Scale (PANSS-30) is the standard instrument for assessing symptoms of schizophrenia and related psychotic disorders. However, its long administration time and structural issues have prompted the development of shorter versions. The PANSS-6, derived through Item Response Theory and Rasch analysis of the PANSS-8, emerged as a potential alternative. Comprising three positive and three negative symptom items, the PANSS-6 offers a more feasible assessment tool. However, its measurement properties have never been systematically reviewed.</div><div>We applied the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) guideline for systematic reviews and meta-analytical procedures to assess the psychometric properties of the PANSS-6. COSMIN comprises several steps: literature search, risk-of-bias assessments, assessing the updated criteria for good measurement properties, grading the quality of the evidence and feasibility aspects.</div><div>We included 13 publications. The PANSS-6 showed sufficient content validity, structural validity, measurement invariance, reliability, criterion validity, construct validity and responsiveness according to COSMIN. On some of them only a small body of evidence is currently available. For internal consistency, cross-cultural validity and measurement error there was not enough evidence for a definite rating. Its short administration time of only 15–20 mins renders feasibility good.</div><div>The PANSS-6 does not cover all schizophrenia symptoms but focuses on the core symptoms in favor of a feasible administration time. The evidence available on its measurement properties yields sufficient results for its purpose - the assessment of symptom severity and its change. According to COSMIN it can potentially be recommended for use.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"94 ","pages":"Pages 41-50"},"PeriodicalIF":6.1000,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924977X25000318","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The Positive and Negative Syndrome Scale (PANSS-30) is the standard instrument for assessing symptoms of schizophrenia and related psychotic disorders. However, its long administration time and structural issues have prompted the development of shorter versions. The PANSS-6, derived through Item Response Theory and Rasch analysis of the PANSS-8, emerged as a potential alternative. Comprising three positive and three negative symptom items, the PANSS-6 offers a more feasible assessment tool. However, its measurement properties have never been systematically reviewed.

We applied the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) guideline for systematic reviews and meta-analytical procedures to assess the psychometric properties of the PANSS-6. COSMIN comprises several steps: literature search, risk-of-bias assessments, assessing the updated criteria for good measurement properties, grading the quality of the evidence and feasibility aspects.

We included 13 publications. The PANSS-6 showed sufficient content validity, structural validity, measurement invariance, reliability, criterion validity, construct validity and responsiveness according to COSMIN. On some of them only a small body of evidence is currently available. For internal consistency, cross-cultural validity and measurement error there was not enough evidence for a definite rating. Its short administration time of only 15–20 mins renders feasibility good.

The PANSS-6 does not cover all schizophrenia symptoms but focuses on the core symptoms in favor of a feasible administration time. The evidence available on its measurement properties yields sufficient results for its purpose - the assessment of symptom severity and its change. According to COSMIN it can potentially be recommended for use.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

European Neuropsychopharmacology 医学-精神病学

CiteScore

10.30

自引率

5.40%

发文量

730

审稿时长

41 days

期刊介绍： European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.